 Tiziana Life Sciences PLC LON:TILS, NASDAQ:TLSA said its breakthrough fully-human monoclonal antibody induces immunomodulatory effects capable of providing clinical benefit when administered nasally. The latest data come from a phase I assessment of Foralumab, which is being developed for a range of neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis and Alzheimers disease. 